Epizyme Appoints CEO
This article was originally published in Scrip
Epizyme, Inc., a clinical stage biopharmaceutical R&D company creating epigenetic therapeutics for cancer patients, has named Robert Bazemore president and CEO, effective Sept. 10, 2015. Bazemore will also join the Epizyme board of directors. He succeeds Dr Robert Gould who has served on the Epizyme board of directors since 2008 and as CEO for the past five-and-a-half years. Following the transition, Gould will continue to serve on the board and as a consultant to the company.
You may also be interested in...
Second quarter venture capital investment in biotech fell from the same period a year ago, but the total remains near record levels, since some early-stage companies have been able to raise big VC sums.
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.